ClinicalTrials.gg
RecruitingNCT05427383Updated Dec 19, 2023

KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy

A Phase 2/3 interventional study of KN026/Placbo Injection and Paclitaxel Injection in Stomach Cancer, sponsored by Shanghai JMT-Bio Inc.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-19.

Sponsored by Shanghai JMT-Bio Inc. (part of CSPC Pharmaceutical Group Limited) · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Apr 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
286
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,184 studies in Stomach Neoplasms with a site in China — 481 open to participants now, 557 under way, 50 of them phase 3. Stomach Neoplasms · China.

Planned enrollment
204th of 881
286 · median 87
Started
2022
with 104 others
Phase 2/3
24 of 1,184
8 open now
Primary completion
2025-11
later than 173 of 556 live
Registered
622nd of 1,184
by date

Among the 1,184 studies in Stomach Neoplasms with a site in China, this one is the 204th largest by planned enrollment of the 881 interventional ones that give a count, is one of 105 that started in 2022, is one of 24 in phase 2/3, reaches primary completion later than 173 of the 556 other live ones, and was the 622nd registered.

Stomach Neoplasms

3,404 studies on the registry are indexed under Stomach Neoplasms; 996 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

481 of the 1,184 studies in Stomach Neoplasms with a site in China are open now. Recruiting first, the newest first:

476 more — sign in →

All 481 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 705 Stomach Neoplasms studies recruiting now, 377 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 70 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,184 studies in Stomach Neoplasms with a site in China, or all of them as a file.
02

Study summary

KN026-001 is a two-stage study (Open-label stage/Randomized stage). Open-label stage is designed to evaluate the safety and efficacy of KN026 and chemotherapy when given together. Randomized stage is designed to evaluate the OS and PFS in patients receiving KN026 and chemotherapy compared to patients receiving placebo and chemotherapy.

Read the detailed description

KN026-001 is a two-stage randomized, multicenter, phase Ⅱ/Ⅲ clinical study to evaluate the efficacy of KN026 in combination with chemotherapy in subjects with HER2-positive advanced unresectable or metastatic gastric cancer, including adenocarcinoma of the gastro-esophageal junction, who have failed first-line therapy.

Stage 1 is an open-label, multicenter, phase Ⅱ study to evaluate the safety and ORR in subjects receiving KN026 in combination with chemotherapy. Stage 2 is a randomized, double-blind, placebo-controlled phase Ш study to evaluate the OS and PFS in subjects receiving KN026 in combination with chemotherapy compared to placebo in combination with chemotherapy.

03

Conditions studied

  • Stomach Cancer

Browse trials for

Keywords

  • Stomach Neoplasm
  • Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years;
  2. Histologically or cytology-confirmed -positive locally advanced, recurrent, or gastric cancer (including adenocarcinoma of the gastro-esophageal junction); HER2 positive is defined as IHC 3+, or IHC 2+ with ISH test positive (HER2/CEP17 ratio ≥ 2.0, or mean HER2 copy number ≥ 6.0 signals/cell);
  3. Failure of at least standard therapy (trastuzumab plus chemotherapy); Note: /adjuvant therapy previously administered with a trastuzumab-containing regimen can be considered first-line therapy if the subject has progressed disease during neoadjuvant/adjuvant therapy or within 6 months of completion of treatment;
  4. Stage 1 : At least one at baseline according to 1.1; Stage 2: At least one evaluable lesion at baseline according to RECIST 1.1; the area must not have received previous radiotherapy, or there must be evidence of significant progression after the end of radiotherapy;
  5. Performance Status of 0 to 1.
  6. ≥ 3 months.
  7. 7. The function of major organs must meet the following criteria : (Hb) ≥ 90 g/L; Absolute neutrophil (ANC) ≥ 1.5×10\^9/L; (PLT) ≥ 90×10\^9/L; (No whole blood or component blood transfusion in the last 14 days; no pro-hematopoietic cytokines used in the last 7 days); , ALT ≤2.5× (upper limit of normal value) (if liver metastases, AST, ALT ≤5×ULN); Total (TBIL) ≤1.5×ULN; Albumin≥ 28 g/L; ≥ 50 mL/min (standard Cockcroft-Gault formula applied); (APTT) ≤ 1.5×ULN, international normalized ratio (INR)/or prothrombin time (PT) ≤ 1.5×ULN; (It is allowed to receive anticoagulants at low stable doses, eg at a dose of aspirin 100 mg/day);
  8. (LVEF) ≥ 50% or lower limit of normal (LLN) in local sites, measured by echocardiography (ECHO), cardiac radionuclide scanning (MUGA) only in the absence of ECHO, with consistency at baseline and follow-up measurements;
  9. Subjects agreed to use effective during the study and for 6 months after the last dose (women of childbearing age must confirm a negative serum pregnancy test within 7 days prior to enrollment);
  10. Female and male patient of childbearing age must agree to take adequate contraceptive measures during the entire study period and through at least 6 months after the last dose of study drug. (Women of childbearing age must have a negative pregnancy test prior to study entry.)
  11. Subjects are able and willing to comply with the study protocol.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with untreated active ; Subjects will be admitted if their brain metastases have been treated and the are stable (brain imaging at least 4 weeks prior to the first dose showed stable lesions with no new CNS symptoms, or CNS symptoms have returned to baseline and no hormonal therapy is required at least 14 days prior to the first dose of the treatment), and there is no evidence of new or enlarged original brain metastases;
  2. Other investigational medications received within 4 weeks prior to the first study treatment, based on the time of the last trial dose;
  3. Antineoplastic therapy such as chemotherapy, small molecule inhibitors, immunotherapy (such as interleukin, interferon, or thymosin) within 4 weeks or 5 half-lives (whichever is shorter but at least 2 weeks) prior to the first study treatment; Have received Chinese herbal treatment with antitumor activity within 14 days before administration;
  4. Subjects recieved major surgery (e.g., transabdominal, transthoracic, etc.) within 28 days prior to the first study treatment; does not include minor procedures such as diagnostic puncture or infusion device implantation), or major surgery is expected to be required during the study;
  5. Previous cumulative doses of doxorubicin exceeding 320 mg/m\^2, or equivalent conversion of other anthracyclines (anthracycline equivalent: 1 mg doxorubicin = 2 mg epirubicin = 2 mg pyrrubicin = 2 mg daunorubicin = 0.5 mg normethoxydaunorubicin = 0.45 mg mitoxantrone; except doxorubicin liposomes);
  6. Previous use of anti- therapy other than trastuzumab (eg, ADC, dual-antibody, small molecule targeted therapy, etc.).
  7. Pregnant or lactating women; or intend pregnancy during the trial or within 6 months of the end of the trial;
  8. Subjects with a history of life-threatening allergies or known allergies to protein drugs or recombinant proteins or to one of in KN026 drugs (histidine, glacial acetic acid, sucrose, and polysorbate 20) who have had a severe reaction to trastuzumab.
  9. Adverse events have not returned to 5.0 grade ≤ grade 1 or baseline from previous anti-tumor treatments , except for alopecia, skin pigmentation and those assessed by the investigators without potential safety risk.
  10. Uncontrollable diarrhoea (≥grade 2 that does not improve within 48 hours of medication);
  11. Subjects with the following history of cardiovascular disease:

    • Subjects with uncontrolled hypertension (defined as sustained systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg despite antihypertensive medication);
    • Any history of symptomatic congestive heart failure ( classification II-IV); the absolute value of decreased by ≥10% and absolute value \< 50% , or the absolute value of LVEF decreased by ≥15% , during or after treatment with trastuzumab or other anti-HER2 treatment;
    • History of myocardial infarction within 6 months before treatment of the first dose;
    • Subjects with angina and unstable angina within three months prior to treatment in the first dose;
    • Severe arrhythmias and conduction abnormalities requiring antiarrhythmic therapy other than β-blockers or digoxin (except atrial fibrillation and paroxysmal supraventricular tachycardia) within 6 months prior to treatment in the first dose;
    • > 450 ms (male); QTcF > 470ms (Female);
    • Other heart diseases that the investigators consider ;
  12. Poorly controlled systemic diseases judged by investigators, including diabetes;
  13. Severe chronic or active infections requiring systemic antibacterial, antifungal, or antiviral therapy (eg, anti-infective drugs have been used for more than 1 week before the trial and will continue to be used), including tuberculosis infection;
  14. Received systemic (> 10 mg/day of prednisone, or equivalent amounts of other corticosteroids) within 2 weeks prior to treatment in the first dose; inhaled steroids or topical cortisol is permitted, corticosteroids are allowed for pre-treatment of certain chemotherapy drugs, and short-term (≤ 7 days) are allowed for the prevention or treatment of contrast allergy;
  15. History of noninfectious interstitial lung disease, or interstitial pneumonia requiring hormonal therapy;
  16. History of immunodeficiency, including positive or other acquired or congenital immunodeficiency disease, or a history of organ transplantation;
  17. Active [HBsAg or HBcAb-positive with HBV DNA > 500 IU/mL (or 2500 copies/mL)] or infection [subjetcs with polymerase chain reaction (PCR)-negative HCV ribonucleic acid (RNA) can participate in this study] or HIV-positive or syphilis antibody positive (confirmed);
  18. History of any other malignant tumors within five years prior to the first dose, except cured cutaneous squamous cell carcinoma, basal cell carcinoma, non-muscle-invasive bladder cancer, localized low-risk prostate cancer [defined as stage ≤ T2a, Gleason score ≤ 6, and PSA ≤ 10 ng/mL at prostate cancer diagnosis (if measured) who have received radical therapy and no biochemical recurrence of prostate-specific antigen (PSA) can participate in this study], cervical/breast cancer in situ who have received radical treatment without any signs of recurrence and metastasis;
  19. Cavity effusion (pleural effusion, ascites, pericardial effusion, etc.) requiring drainage or diuretic therapy, within 2 weeks prior to the first dose of treatment; Diuretics for other reasons are permitted;
  20. Known mismatch repair deficient (dMMR) or highly unstable microsatellite (MSI-H) without previous /PD-L1 monoclonal antibody therapy;
  21. Unintentional weight loss of ≥5% within 1 month prior to the first dose, despite peripheral or central venous nutritional support;
  22. Inability to tolerate or refuse chemotherapy required by the protocol;
  23. The investigator considered the subject to be unsuitable for participation in this clinical study due to the presence of any clinical or laboratory abnormalities or history of systemic disease or other reasons.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
286 participants (estimated)

Study arms

  • Experimental
    KN026 + Paclitaxel/ Docetaxel/ Irinotecan

    IV KN026 at 30 mg/kg on D1 and IV Paclitaxel at 175 mg/m² on D1 or IV Docetaxel at 75 mg/m² on D1 or IV Irinotecan at 125 mg/m² on D1, D8, Q3W

    Drug: KN026/Placbo Injection · Drug: Paclitaxel Injection · Drug: Docetaxel Injection · Drug: Irinotecan Injection

  • Experimental
    Placebo + Paclitaxel/ Docetaxel/ Irinotecan

    IV Placebo at 30 mg/kg on D1 and IV Paclitaxel at 175 mg/m² on D1 or IV Docetaxel at 75 mg/m² on D1 or IV Irinotecan at 125 mg/m² on D1, D8, Q3W

    Drug: KN026/Placbo Injection · Drug: Paclitaxel Injection · Drug: Docetaxel Injection · Drug: Irinotecan Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) according to RECIST 1.1 by IRC

    The time from the first dose of study treatment to the date of documented disease

    Time frame: Up to 2.5 years

  2. Overall Survival (OS) according to RECIST 1.1 by IRC

    The time from the first dose of study treatment until the date of death from any cause

    Time frame: Up to 2.5 years

Secondary outcomes

  1. ORR according to RECIST 1.1 by Investigator's Assessment and IRC

    The percentage of patients with a complete response (CR) or partial response (PR)

    Time frame: Up to 2.5 years

  2. DCR according to RECIST 1.1 by Investigator's Assessment and IRC

    Number of subjects who achieved a best response of CR, PR, or SD during treatment

    Time frame: Up to 2.5 years

  3. DOR according to RECIST 1.1 by Investigator's Assessment and IRC

    The time from the first objective response (CR or PR) to documented PD, clinical progression, or death from any cause

    Time frame: Up to 2.5 years

  4. Progression Free Survival (PFS) according to RECIST 1.1 by Investigator's Assessment

    The time from the first dose of study treatment to the date of documented disease

    Time frame: Up to 2.5 years

  5. Frequency and Severity of Adverse Events according to NCI CTCAE 5.0

    Number of participants with treatment-related adverse events as assessed by CTCAE 5.0

    Time frame: Up to 2.5 years

  6. The concentration of KN026 drug in serum

    The concentration of KN026 drug in serum

    Time frame: Up to 2.5 years

  7. Incidence and titer of anti-drug antibody (ADA)

    Incidence and titer of anti-drug antibody (ADA)

    Time frame: Up to 2.5 years

  8. Incidence of neutralizing Antibody,Nab

    Incidence of neutralizing Antibody,Nab

    Time frame: Up to 2.5 years

Other outcomes

  1. To explore the correlation of gene mutation status and the efficacy

    Exploration of drug resistance mechanism , Explore predictive biomarkers

    Time frame: Up to 2.5 years

  2. Subjects will be assessed using the European Quality of Life 5 Dimensions and 5 Lines (EQ-5D-5L) scales

    It is a vertical visual analogue scale that takes values between 100 (best imaginable health) and 0 (worst imaginable health), on which patients provide a global assessment of their health.

    Time frame: Up to 2.5 years

  3. Subjects will be assessed using the Quality of Life Questionnaire-Core 30 (QLQ-C30) scales

    The QLQ-C30 is composed of six functioning scales (including a measure for global quality of life), three symptom scales, and six single items. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.

    Time frame: Up to 2.5 years

  4. Subjects will be assessed using the Quality-of-life Questionnaire Oesophago Gastric module 25 (EORTC QLQ OG25) scales

    Quality-of-life Questionnaire Oesophago Gastric module 25 (EORTC QLQ OG25): Description: All of the scales and single-item measures range in score from 0 to 100. A high score for all the scales and single-items represents a high level of symptomatology or problems.

    Time frame: Up to 2.5 years

  5. Change from baseline in CEA (carcinoembryonic antigen)

    Time frame: Up to 2.5 years

  6. Change from baseline in CA19-9 (carbohydrate antigen 199)

    Time frame: Up to 2.5 years

  7. Change from baseline in CA72-4 (carbohydrate antigen 724)

    Time frame: Up to 2.5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Nov 2025, 43 months after the start.

Of 26 phase 2/3 interventional studies under Stomach Neoplasms, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 52. This study's planned 43 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2022
First posted
Jun 22, 2022
StartActual
Apr 7, 2022
Primary completionEst.
Nov 2025
CompletionEst.
Nov 2026
Last update
Dec 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05427383
Responsible party
Sponsor
First posted
Jun 22, 2022
Start date
Apr 7, 2022
Primary completion
Nov 2025 (estimated)
Completion
Nov 2026 (estimated)
Last update
Dec 19, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion